# LUTATHERA Injection General Use Result Survey

> **NCT05844332** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 347 (actual)

## Conditions studied

- Somatostatin Receptor-positive Neuroendocrine Tumor

## Interventions

- **OTHER:** LUTATHERA

## Key facts

- **NCT ID:** NCT05844332
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2024-06-27
- **Final completion:** 2024-06-27
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844332, "LUTATHERA Injection General Use Result Survey". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05844332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*